سعر فيركايل 100 مجم / 2 مل 5 امبولات حقن وريدى او عضلي 2026

Iron(III)-hydroxide dextran complex solution for injection/infusion, 100 mg iron(III) per 2 ml ampoule (50 mg/ml), for intramuscular or intravenous use; pack of 5 ampoules (Sunny Medical under licence from Laboratoires Sterop, Belgium).

• Adults only: treatment of iron deficiency when oral iron cannot be used (intolerance or demonstrated lack of effect) or when there is a clinical need to replenish iron stores rapidly; diagnosis must be confirmed by laboratory tests.Population: AdultsFederal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium

• Uncommon: anaphylactoid reactions (dyspnoea, urticaria, rash, pruritus, nausea, chills), blurred vision, numbness, flushing, nausea/vomiting, abdominal pain, cramps. Rare: hypotension, arrhythmia, convulsions, injection-site pain and brown skin discoloration. Very rare: severe acute anaphylactoid reactions, haemolysis.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium

• Hypersensitivity to iron dextran or excipients, or known serious hypersensitivity to other parenteral iron.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium
• Non-iron-deficiency anaemia (e.g. haemolytic anaemia); iron overload or disturbed iron utilisation (haemochromatosis, haemosiderosis).International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium
• IV use in patients with a history of asthma, eczema or other atopic allergy.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium

• Parenteral iron can cause serious, potentially fatal anaphylactic/anaphylactoid reactions, even after previously tolerated doses; give only where staff and resuscitation facilities are immediately available and observe the patient for at least 30 minutes after each dose. Risk is higher with allergies, atopy and immune/inflammatory conditions.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium

• Oral iron preparationsDo not combine with oral iron (reduced oral iron absorption); start oral iron no sooner than 5 days after the last injection.Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium

• No adequate controlled studies in pregnant women; use only if absolutely necessary after careful benefit-risk assessment.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium
• No information on excretion into milk; preferably not used during breastfeeding.International label, same formulation · Federal Agency for Medicines and Health Products (FAMHP/AFMPS), Belgium

• Iron(III)-hydroxide dextran complex (iron dextran): Stable iron(III)-hydroxide dextran complex taken up by reticuloendothelial cells (liver, spleen), which split it into iron and dextran; the iron binds to proteins as haemosiderin, ferritin or transferrin and replenishes haemoglobin and iron stores (Belgian Fercayl SmPC 5.1-5.2).